A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
Latest Information Update: 22 Mar 2025
At a glance
- Drugs Lysergide (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms MMED008
- Sponsors Mindmed
- 11 Dec 2024 According to a MindMed media release, data from this study were presented at the ACNP 2024 Congress taking place December 8-11 in Phoenix, AZ.
- 20 Jun 2024 According to a Mindmed media release, company announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD based on the results of this trial.
- 09 May 2024 According to a Mindmed media release, company announced that One-year follow-up data from a Phase 2 placebo-controlled investigator-initiated clinical trial of lysergide in the treatment of anxiety disorders will be presented at the Society of Biological Psychiatry (SOBP) 2024 Annual Meeting being held May 9 to 11 in Austin, Texas.